Saltar al contenido principal
xMedica

NCT07415031ClinicalTrials.gov

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC)…

Fase 2170 participantes buscados101 centros21 países

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-02-17; recorded start 2026-05-06
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 19 other studies in this databaseCounted from the lead sponsor named in the record (Mirati Therapeutics Inc.)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 100 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 170 participants (target), run at 101 sites, across 21 countries.

How this score is built
  • Enrolment21/40

    170 participants (target)

  • Site count23/25

    100 sites

  • Country count15/15

    20 countries

  • Planned duration7/10

    Planned over about 22 months

  • Sponsor scale4/10

    Mirati Therapeutics Inc. has led 19 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.

Afecciones

  • Solid Tumors

Elegibilidad

Elegibilidad
SexoTodos
Edades18 Years – Sin máximo
Voluntarios sanosNo

Elegibilidad tal como figura en el registro

Inclusion Criteria: * Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit. * Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF. Exclusion Criteria: * Participant is not eligible for study treatment per the parent study eligibility criteria. * Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study. * Participants not receiving clinical benefit from parent study drug as assessed by the investigator. Other protocol defined inclusion/exclusion criteria applies.

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioDe intervención
FaseFase 2
AsignaciónNo aplicable
Modelo de intervenciónPARALLEL
Propósito principalTREATMENT
EnmascaramientoNONE (0)
Inscripción170 participantes buscados

Patrocinador y colaboradores

  • Mirati Therapeutics Inc. Patrocinador

Grupos e intervenciones

  • Arm A1EXPERIMENTAL
  • Arm A2EXPERIMENTAL
  • Arm B1EXPERIMENTAL
  • Arm B2EXPERIMENTAL
  • Arm B3EXPERIMENTAL
  • Arm B4EXPERIMENTAL
  • Arm C1EXPERIMENTAL
  • Arm C2EXPERIMENTAL
  • Arm C3EXPERIMENTAL
  • Arm C4EXPERIMENTAL

Intervenciones

  • Fármaco Adagrasib

    Specified dose on specified days

  • Fármaco Cetuximab

    Specified dose on specified days

  • Fármaco Docetaxel

    Specified dose on specified days

  • Fármaco Fluorouracil

    Specified dose on specified days

  • Fármaco Irinotecan

    Specified dose on specified days

  • Fármaco Leucovorin

    Specified dose on specified days

  • Fármaco Oxaliplatin

    Specified dose on specified days

  • Fármaco Pembrolizumab

    Specified dose on specified days

  • Fármaco Pemetrexed

    Specified dose on specified days

Variables de resultado

  1. Variable de resultado principal

    Number of Participants With Adverse Events (AEs)

    Plazo Up to 90 days from last dose or study discontinuation

  2. Variable de resultado principal

    Number of Participants With AEs Leading to Treatment Discontinuation

    Plazo Up to 90 days from last dose or study discontinuation

  3. Variable de resultado principal

    Number of Participants With Serious Adverse Events (SAEs)

    Plazo Up to 90 days from last dose or study discontinuation

  4. Variable de resultado principal

    Number of Participants With AEs Leading to Death

    Plazo Up to 90 days from last dose or study discontinuation

Fechas

Fechas
Fecha de inicio6 de mayo de 2026 (real)
Finalización principal16 de febrero de 2028 (estimada)
Finalización16 de febrero de 2028 (estimada)
Primera publicación17 de febrero de 2026 (real)
Última actualización12 de noviembre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última veznoviembre de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

81 centros están en reclutamiento

Australia

Australia
CentroCiudadEstado o regiónEstado
Local Institution - 0093St LeonardsNew South WalesRetirado

Belgium

Belgium
CentroCiudadEstado o regiónEstado
AZ Maria MiddelaresGhentEn reclutamiento

Brazil

Brazil
CentroCiudadEstado o regiónEstado
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Clinical OncologySão PauloEn reclutamiento
Fundacao Antonio Prudente - AC Camargo Cancer CenterSão PauloEn reclutamiento

Canada

Canada
CentroCiudadEstado o regiónEstado
BC Cancer - VancouverVancouverBritish ColumbiaEn reclutamiento

China

China
CentroCiudadEstado o regiónEstado
Local Institution - 0037BeijingBeijing MunicipalityRetirado
Local Institution - 0038ChangshaHunanRetirado
Local Institution - 0040ChengduSichuanRetirado
Local Institution - 0044HangzhouZhejiangRetirado
Local Institution - 0039JinanShandongRetirado
Local Institution - 0047LinyiShandongRetirado
Local Institution - 0048NanchangJiangxiRetirado
Local Institution - 0046NanjingJiangsuRetirado
Local Institution - 0043ShanghaiShanghai MunicipalityRetirado
Local Institution - 0049ShenyangLiaoningRetirado
Local Institution - 0041Xi'anRetirado
Local Institution - 0045XiamenFujianRetirado
Local Institution - 0042ZhengzhouHenanRetirado

France

France
CentroCiudadEstado o regiónEstado
ICO PapinAngersMaine-et-LoireEn reclutamiento
Chu Jean MinjozBesançonDoubsEn reclutamiento
Hospices Civils de Lyon - Hopital Louis PradelBronRhôneEn reclutamiento
Centre Hospitalier Intercommunal de CréteilCréteilEn reclutamiento
L Hopital Nord OuestGleizéRhôneEn reclutamiento
Chu Grenoble AlpesLa TroncheIsèreEn reclutamiento
Assistance Publique Hôpitaux de Marseille - Hôpital NordMarseilleEn reclutamiento
Centre Hospitalier Universitaire de Nice - Hopital PasteurNiceAlpes-MaritimesEn reclutamiento
Centre Antoine-LacassagneNiceAlpes-MaritimesEn reclutamiento
Groupe hospitalier Paris saint JosephParisÎle-de-France RegionEn reclutamiento
CHU Bordeaux Haut-LevequePessacAquitaineEn reclutamiento
Local Institution - 0051PoitiersVienneRetirado
Centre Hospitalier de Cornouaille Quimper - ConcarneauQuimperEn reclutamiento
Institut de Cancérologie de l'OuestSaint-HerblainLoire-AtlantiqueEn reclutamiento
Hôpital Nord Guillaume-et-René-Laennec / CHU de NantesSaint-HerblainLoire-AtlantiqueEn reclutamiento
Hôpital d'Instruction des Armées BéginSaint-MandéEn reclutamiento
Nouvel Hôpital Civil (NHC)StrasbourgAlsaceEn reclutamiento
Centre Hospitalier Régional Universitaire de Tours - Hôpital BretonneauToursEn reclutamiento

Germany

Germany
CentroCiudadEstado o regiónEstado
Klinikum NeuperlachMünchenEn reclutamiento

Greece

Greece
CentroCiudadEstado o regiónEstado
Alexandra General Hospital of AthensAthensAttikíEn reclutamiento
Metropolitan HospitalAttikiEn reclutamiento
Theagenio HospitalThessalonikiKentrikí MakedoníaEn reclutamiento

Hungary

Hungary
CentroCiudadEstado o regiónEstado
Orszagos Koranyi Pulmonologiai IntezetBudapestEn reclutamiento
Orszagos Onkologiai IntezetBudapestEn reclutamiento

Israel

Israel
CentroCiudadEstado o regiónEstado
Bnai Zion Medical CenterHaifaEn reclutamiento
Shaare Zedek Medical CenterJerusalemJerusalemEn reclutamiento
Tel Aviv Sourasky Medical Center - Oncology - Hematology/OncologyTel AvivEn reclutamiento

Italy

Italy
CentroCiudadEstado o regiónEstado
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'OrsolaBolognaEn reclutamiento
Azienda Ospedaliera Universitaria CareggiFlorenceTuscanyEn reclutamiento
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"MeldolaEmilia-RomagnaEn reclutamiento
Istituto Europeo di Oncologia IRCCSMilanEn reclutamiento
Istituto Europeo di Oncologia IRCCSMilanEn reclutamiento

En el registro figuran 51 centros más.

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

  1. 27 de octubre de 2026

    Centro eliminado

    1 site removed (101 total)

    102101

  2. 9 de octubre de 2026

    Centro añadido

    2 sites added (102 total)

    100102

  3. 18 de agosto de 2026

    Centro eliminado

    1 site removed (100 total)

    101100

  4. 27 de julio de 2026

    Centro añadido

    1 site added (101 total)

    100101